Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 143 of the 143 references it cites were found in a registry or an index.

Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract

Open access

Abstract

Aims: To objectively appraise evidence for possible adverse effects of long-term statin therapy on glucose homeostasis, cognitive, renal and hepatic function, and risk for haemorrhagic stroke or cataract. Methods and results: A literature search covering 2000-2017 was performed. The Panel critically appraised the data and agreed by consensus on the categorization of reported adverse effects. Randomized controlled trials (RCTs) and genetic studies show that statin therapy is associated with a modest increase in the risk of new-onset diabetes mellitus (about one per thousand patient-years), generally defined by laboratory findings (glycated haemoglobin ≥6.5); this risk is significantly higher in the metabolic syndrome or prediabetes. Statin treatment does not adversely affect cognitive function, even at very low levels of low-density lipoprotein cholesterol and is not associated with clinically significant deterioration of renal function, or development of cataract. Transient increases in liver enzymes occur in 0.5-2% of patients taking statins but are not clinically relevant; idiosyncratic liver injury due to statins is very rare and causality difficult to prove. The evidence base does not support an increased risk of haemorrhagic stroke in individuals without cerebrovascular disease; a small increase in risk was suggested by the Stroke Prevention by Aggressive Reduction of Cholesterol Levels study in subjects with prior stroke but has not been confirmed in the substantive evidence base of RCTs, cohort studies and case-control studies. Conclusion: Long-term statin treatment is remarkably safe with a low risk of clinically relevant adverse effects as defined above; statin-associated muscle symptoms were discussed in a previous Consensus Statement. Importantly, the established cardiovascular benefits of statin therapy far outweigh the risk of adverse effects.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehy182

Cites

143 of 143 references verified0 citation errors · 0 not checkable

Statistics

Figures

Image 1
CC BY-NC · PubMed Central
Figure 1 Overview of the relative prevalence of the main types of adverse effects reported with statin therapy. RCT, randomized controlled trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels.
Figure 1 Overview of the relative prevalence of the main types of adverse effects reported with statin therapy. RCT, randomized controlled trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels.CC BY-NC · PubMed Central
Figure 2 Factors favouring diabetogenic effects of statins and candidate mechanisms in extrahepatic tissues and pancreatic beta-cells. AKT, alpha serine-threonine-protein kinase; ATP, adenosine triphosphate; CoQ10, Coenzyme Q10, also known as ubiquinone; FBG, fasting blood glucose; GLUT, glucose transporter; HbA1c, glycated haemoglobin; HMG CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; LDLR, low-density lipoprotein receptor; NLRP3, NOD-like receptor family, pyrin domain containing 3.
Figure 2 Factors favouring diabetogenic effects of statins and candidate mechanisms in extrahepatic tissues and pancreatic beta-cells. AKT, alpha serine-threonine-protein kinase; ATP, adenosine triphosphate; CoQ10, Coenzyme Q10, also known as ubiquinone; FBG, fasting blood glucose; GLUT, glucose transporter; HbA1c, glycated haemoglobin; HMG CoA reductase, 3-hydroxy-3-methylglutaryl coenzyme A reductase; LDLR, low-density lipoprotein receptor; NLRP3, NOD-like receptor family, pyrin domain containing 3.CC BY-NC · PubMed Central
Figure 3 Factors that may affect susceptibility to drug induced liver injury, either by influencing drug metabolism or transport mechanisms.
Figure 3 Factors that may affect susceptibility to drug induced liver injury, either by influencing drug metabolism or transport mechanisms.CC BY-NC · PubMed Central
Take home figure The cardiovascular benefit of long-term statin therapy far outweighs potential risks. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels.
Take home figure The cardiovascular benefit of long-term statin therapy far outweighs potential risks. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein cholesterol; RCT, randomized controlled trial; SPARCL, Stroke Prevention by Aggressive Reduction in Cholesterol Levels.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 143 references

Cited by

See all 370

Metadata

Authors
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., Krauss, R. M., Laufs, U., Leiter, L. A., März, W., Nordestgaard, B. G., Raal, F. J., Roden, M., Santos, R. D., Stein, E. A., Stroes, E. S., Thompson, P. D., Tokgözoğlu, L., Vladutiu, G. D., Gencer, B., Stock, J. K., Ginsberg, H. N., Chapman, M. J., & European Atherosclerosis Society Consensus Panel
Affiliations
  • University Hospital of Geneva (CH)
  • Imperial College London (GB)
  • Sahlgrenska University Hospital (SE)
  • University of Milan (IT)
  • National Institute for Health and Medical Research (INSERM) UMRS1166, Department of Endocrinology-Metabolism, ICAN—Institute of CardioMetabolism and Nutrition, AP-HP, Hôpital de la Pitié, Paris, France
  • Department of Public Health, University Hospital Ghent, Ghent, Belgium
  • Western University (CA)
  • Amsterdam UMC Location University of Amsterdam (NL)
  • Emory University (US)
  • Department of Atherosclerosis Research, Children's Hospital Oakland Research Institute, Oakland, CA, USA
  • Leipzig University (DE)
  • St. Michael's Hospital (CA)
  • University of Graz (AT)
  • University of Copenhagen (DK)
  • University of the Witwatersrand (ZA)
  • Deutsches Diabetes-Zentrum e.V. (DE)
  • Universidade de São Paulo (BR)
  • Metabolic and Atherosclerosis Research Center, Cincinnati, OH, USA
  • Hartford Hospital (US)
  • Hacettepe University (TR)
  • University at Buffalo, State University of New York (US)
  • Division of Cardiology, Department of Medical Specialties, Foundation for Medical Researches, Geneva University Hospital, Rue Gabrielle-Perret-Gentil 4 1205 Geneva, Switzerland
  • European Atherosclerosis Society (SE)
  • Columbia University (US)
  • Inserm (FR)
Corresponding author
Mach, François
Venue
European Heart Journal
Published
2018-04-27
Volume
39
Issue
27
Pages
2526-2539
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2801534920
Cited by
370
References
143
Citations by year
2026: 23 · 2025: 27 · 2024: 49 · 2023: 40 · 2022: 57 · 2021: 43 · 2020: 50 · 2019: 57 · 2018: 23
FWCI
45.21
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
  • HAL (submittedVersion)
  • Archivio Istituzionale della Ricerca (Universita Degli Studi Di Milano) (submittedVersion, other-oa)
  • eScholarship (California Digital Library) (submittedVersion)
  • eScholarship (California Digital Library) (submittedVersion, cc-by-nc)
  • IRIS (submittedVersion)
  • Hacettepe University Institutional Repository (hacettepe.edu.tr) (submittedVersion, other-oa)
  • Spiral (Imperial College London) (submittedVersion, other-oa)
Funders
  • European Atherosclerosis Society
  • Amgen, AstraZeneca, Eli Lilly, Esperion, Merck, Pfizer, and Sanofi-Regeneron
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
  • Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
Keywords
statins, adverse drug reactions, glucose homeostasis, new-onset diabetes, cognitive function, renal function, liver function, hemorrhagic stroke, cataract, statin-induced liver injury, metabolic syndrome, prediabetes, LDL cholesterol, drug safety
MeSH terms
Cataract, Cerebral Hemorrhage, Cognition Disorders, Glucose, Homeostasis, Humans, Kidney Diseases, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Stroke, Chemical and Drug Induced Liver Injury

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. https://app.cochat.ai/papers/10.1093/eurheartj/ehy182
The paper
Mach, F., Ray, K. K., Wiklund, O., Corsini, A., Catapano, A. L., Bruckert, E., De Backer, G., Hegele, R. A., Hovingh, G. K., Jacobson, T. A., Krauss, R. M., Laufs, U., Leiter, L. A., März, W., Nordestgaard, B. G., Raal, F. J., Roden, M., Santos, R. D., Stein, E. A., . . . European Atherosclerosis Society Consensus Panel. (2018). Adverse effects of statin therapy: perception vs. the evidence – focus on glucose homeostasis, cognitive, renal and hepatic function, haemorrhagic stroke and cataract. European Heart Journal. https://doi.org/10.1093/eurheartj/ehy182

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.